Members of the Red Cross bury people who have died of Ebola in Rwampara in the DRC, guarded by military personnel after attacks on a treatment facility for Ebola patients.

The World Health Organization’s (WHO) Director General has called for an immediate ceasefire in the eastern DRC to enable officials to address the outbreak of a particularly deadly strain of Ebola, warning that stopping transmission “depends entirely on humanitarian access”.

The DRC’s Ituri province, the heart of the Ebola Bundibugyo virus outbreak, is facing “a catastrophic collision of disease and conflict”, Tedros warned on Wednesday.

The DRC army and the M23 rebel group are locked in combat, largely focused on control over the region’s minerals.

“Ongoing clashes are driving mass displacement, pushing exposed contacts into overcrowded camps and severing critical containment corridors. Frontline workers are risking everything, while attacks on health facilities make tracking cases and their contacts nearly impossible,” Tedros warned.

The Africa Centres for Disease Control and Prevention has warned that the outbreak could infect up to 7,500 people. On 23 May, it reported almost 1000 suspected cases and over 100 deaths.

However, it is difficult to confirm cases as samples from the outbreak zone must travel 1,700 kilometres  – often on rudimentary roads – to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo.

The conflict has also made it difficult for health officials to provide residents with information about the outbreak, for which there are no approved vaccines or treatments, and a death rate of up to 50%. 

Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death.

In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled

“We cannot build community trust or isolate the sick while bombs are falling,” said Tedros. “We urge all warring parties to agree to an immediate ceasefire to contain this outbreak. To allow us safe and sustained access for medical teams.”

Travel restrictions

Last week, the United States (US) closed its borders to citizens from the DRC, Uganda and South Sudan, and this week it emerged that US citizens exposed to the virus in these African countries will be quarantined in Kenya rather than flown home.

This week, Canada also closed its borders to the same three countries.

However, a spokesperson for the European Centre for Disease Prevention and Control (ECDC) said on Wednesday that “the risk of infection to the general population in Europe remains very low”, but stressed that it is “crucial to reduce risk by identifying travellers who are symptomatic”.

The  ECDC is assisting the European Union and European Economic Area (EU/EEA) to “rapidly detect and isolate anyone infected who is arriving from the regions affected and carry out all necessary control measures”.

It has also deployed an ECDC expert to the Africa CDC to support its response.

Meanwhile, Uganda – which has confirmed 17 cases – has closed its border with the DRC. Within the DRC, flights to Bunia in Ituri have been suspended, both containing the outbreak and making humanitarian efforts more difficult.

Race for vaccines, treatment

Meanwhile, scientists are racing to adapt current Ebola research, which is focused on the more widespread Zaire strain, to address the Bundibugyo outbreak.

There are plans to extend a Phase 3 trial of the oral antiviral treatments, remdesivir (Obeldesivir) and Molnupiravir, to include the highest-risk contacts of people infected with Bundibugyo, testing whether they can stop or minimise infection within the 21-day infection period.

Dr Marie Jaspard, a French infectious disease researcher who heads the Ebola Post-Exposure Prophylaxis (EboPEP) research group, told a WHO scientific webinar earlier this week that scientists are redesigning the protocol as fast as they can, but that suitable high-risk contacts will be able to receive treatment immediately.

Obeldesivir is an oral form of remdesivir, which is suitable for remote settings, although its safety in children and pregnant women has not yet been established. 

Molnupiravir, which proved effective against COVID‑19 experience, has shown some efficacy against Ebola in animal studies

The most advanced treatment candidate for Bundibugyo is MBP134, “a cocktail of two broad-spectrum monoclonal antibodies, capable of neutralising several viral species of Orthoebolavirus”, which has already been tested on primates, according to the French scientific research agency, ANRS.

But this has to be injected, making it less suitable for remote areas such as Ituri.

Meanwhile, DRC Health Minister Roger Kamba said that his country has requested access to a monoclonal antibody tested against all three Ebola strains – Zaire, Sudan, and Bundibugyo – that has been developed in the US.

The DRC has officially requested access to this experimental treatment to launch a clinical trial for confirmed patients.

Image Credits: AP, Africa CDC.

Temperature projections from the World Meteorological Organization (WMO) warn that temperatures will rise further in the next five years.

Global average temperatures are likely to reach record levels in the coming five years, the latest report from the World Meteorological Organization (WMO) warns, released amid news that the UK recorded its hottest day in May ever earlier this week.

Temperatures in the Arctic region are expected to continue to be higher than the global mean, according to the report produced by the United Kingdom’s Met Office and released on Thursday.

A record-breaking heatwave is sweeping across Europe, causing misery and deaths in some European countries. On Wednesday, the temperature at Heathrow Airport in London reached 35°C, the hottest day in May recorded in the UK. In some parts of France and in Spain temperatures were higher by as much as 10°C compared to normal.

The WMO’s report suggests that such brutal summers will become the norm in the near future. The annual global mean near-surface temperatures during 2026–2030 are projected to range between 1.3°C and 1.9°C above the 1850-1900 average.

“There is an El Niño predicted for the end of 2026, which increases the chances of the following year, 2027, being the next record-breaking year,” said Dr Leon Hermanson, the report’s lead author.

There is an 86% chance that one of the years between 2026 and 2030 will surpass 2024 as the warmest year on record, according to the update.

Paris Agreement target in danger

The Paris Agreement target of 1.5°C is likely to be breached more often in the coming years.

In 2015, global leaders agreed to try to limit global warming to 1.5°C above the pre-industrial era. The target was seen as being an example of low ambition by several low-lying countries and climate advocates. However, the world briefly breached this target in 2024 when the global average surface temperature was about 1.55 °C.

The WMO report now finds that there is a 91% chance that the global mean near-surface temperature will temporarily exceed 1.5°C above the 1850-1900 between 2026 and 2030.

It is also likely (75% chance) that the 2026-2030 five-year mean will exceed 1.5°C above the 1850-1900 average.

For now, the 2°C mark seems to be safe and some time away. The WMO report said that it is considered exceptionally unlikely (less than 1%) that any single year will exceed 2°C above the 1850-1900 average in the next five years.

With every half-degree temperature rise, the sea levels rise and put communities living in low-lying areas in danger.

Arctic warming at record pace

Glacier
The Arctic region has been especially affected by climate change.

The Arctic region is fast warming at a record pace. Arctic temperatures over the next five extended northern hemisphere winters (November-March) are predicted to be 2.8°C above average temperatures for 1991-2020. This is more than three and half times that of global mean temperature anomaly over the same period.

Projections of Arctic sea-ice for March 2026-2035 suggest that there will be further reductions in sea-ice concentration in the Barents Sea, Bering Sea, and Sea of Okhotsk.

The rainfall and snowfall patterns are also changing. While some areas are projected to get wetter, others are projected to get drier.

In the tropics and in high latitudes, the precipitation is expected to increase compared to the 1991-2020 reference period. Precipitation is expected to decrease in the subtropics, particularly in the southern hemisphere, where a warmer climate is expected.

For May-September 2026-2030, the report suggests higher precipitation in the Sahel, northern Europe, Alaska and Siberia. But Amazon is likely to be drier during this period which will also make it prone to forest fires.

A guide for policymakers

Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers.
Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers.

The 1.5°C and 2.0°C levels specified in the Paris Agreement refer to long-term warming sustained over an extended period, and not just one year. Typically, this period is at least two decades long.

Individual years with annual global mean temperatures exceeding these levels do not mean that the long-term temperature goals of the Paris Agreement are out of reach.

These reports are meant to guide policymakers as they formulate policies to reduce global carbon emissions. Around 13 different institutions contributed data to this report, increasing the reliability of the results.

Image Credits: WMO, Unspash/Mika Baumeister, Melissa Bradley, Unsplash/Ernests Vaga.

Afrigen CEO Prof Petro Terblanche.

Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials.

The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday.

This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards.

“Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors.

Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council.

Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. 

“We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.”

Afrigen’s 15 partners  – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals.

Huge challenge of sustainability

Charles Gore, head of the Medicines Patent Pool.

MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”.

“The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore.

“What has developed here [has been] transferred out across LMICs to make the world a better and safer place.”

However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”.

This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies.

As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. 

Milestone for Africa

Dr Claudia Nannei, WHO’s team lead in product development and manufacturing

WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. 

“Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “

Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”.

Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen.

Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement.

“It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.”

Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination.
Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination.

The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement.

Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries.

Professor Miriam Mutebi highlights critical global mortality rates.
Miriam Mutebi highlights critical global mortality rates.

The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures.

“Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination.

The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually.

The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population.
The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population.

Low- and middle-income countries bear the highest burden

The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion.

While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030.

Namgyal stresses the need for systems-level policy implementation.
Jennifer Namgyal stresses the need for systems-level policy implementation.

Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts.

This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems.

“The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch.

Regional successes in fighting cervical cancer

Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries.
Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries.

The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment.

“Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal.

After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14.

Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics.

Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing.

Shortfalls, ODA cuts and lack of data

Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy.
Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy.

Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets.

“It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal.

To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management.

However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control.

Confronting complex epidemiological threats

HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer.

The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both.

Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence.

To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance.

“We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said.

Sharing resources across vast borders

From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF).
From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF).

Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier.

The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints.

This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities.

To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said.

Community engagement versus misinformation

Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information.
Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information.

While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts.

The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%.

Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys.

“Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal.

However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings.

Non-binding approach, fiscal constraints

With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions.

Ambassador Leslie Ramsammy demands cross-border cooperation.
Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation.

“This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan.

“Economic status and geography should not bring death to our doors.”

However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets.

Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods.

See also:

Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa

Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026.

Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026.

Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA).

The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty.

Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body.

A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka.

He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline.

He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control.

While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities.

In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases,

“So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said.

He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy.

“The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said.

Shining a spotlight on snakebites

Millions are bitten by snakes every year, and struggle to access care.

An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO.

Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment.

Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings.

“His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony.

Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini.

“This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement.

“Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added.

The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO.

Climate change is worsening inequities in health 

Sania Nishtar, CEO of the global vaccine alliance Gavi.

The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas.

“There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi.

She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign.

The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006.

“He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region.

“His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added.

Image Credits: WHO, WHO.

From left to right: Suerie Moon (GHC), Viroj Tangcharoensathien (IGWG), Matthias Seiche (Germany), and Maria Van Kerkhove (WHO) discuss pandemic preparedness.
From left to right: Suerie Moon (GHC), Viroj Tangcharoensathien (IGWG), Matthias Seiche (Germany), and Maria Van Kerkhove (WHO) discuss pandemic preparedness.

WHO emergency funds are running low, and global health leaders are concerned about a systemic paralysis in pandemic preparedness. In high-level discussions in Geneva, experts explored the geopolitical rifts, pitting the Global South’s demand to treat pandemic tools as legally binding “public goods” against a European push for market-driven surge financing.

As a severe Ebola outbreak spreads among vulnerable populations in the Democratic Republic of the Congo and Uganda, the financial gridlock in global pandemic preparedness funding is taking a measurable human toll. The escalating emergency serves as a grim reminder that “nature does not wait for humans to finish treaty negotiations,” Professor Suerie Moon, co-director of the Global Health Centre (GHC) at the Geneva Graduate Institute, noted at a high-level forum in Geneva.

Maria Van Kerkhove warns of dangerously low emergency funds.
Maria Van Kerkhove (WHO) warns of dangerously low emergency funds.

Public health leaders warned at the event that the threat from infectious diseases and pandemic preparedness are severely neglected while nations simultaneously ramp up military defence and border security spending.

Expressing her frustration over these skewed global priorities, Dr Maria Van Kerkhove, acting director of the department of epidemic and pandemic management at the World Health Organization (WHO), noted that the agency’s contingency fund for emergencies is “dangerously low right now.”

“You can spend billions of dollars a day on a war, and we don’t have money for this,” she stated, calling the constant struggle for health financing “ridiculous” during the panel discussions.

Co-hosted by the GHC, the WHO, the European Commission, and the governments of Indonesia and Germany, the forum convened a diverse coalition of decision-makers.

Alongside Van Kerkhove, Dr Viroj Tangcharoensathien, vice-chair of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement, and Matthias Seiche, head of health policy and financing at Germany’s Federal Ministry for Economic Cooperation and Development, offered contrasting visions over approaches to crisis funding. They were followed by a technical panel of specialised agencies that explored practical implementation, moderated by GHC’s Head of Policy Engagement, Daniela Morich.

The debate exposed a deep ideological rift: while low- and middle-income countries are demanding legally binding treaties that mandate equitable access to life-saving tools as a universal public good, western states are pushing for market-based financial mechanisms to quickly mobilise capital in the event of a crisis.

Championing pandemic preparedness as a ‘public good’

From left to right: Daniela Morich (GHC), Janet Ginnard (Unitaid), Jutta Reinhard-Rupp (FIND), and Aurélia Nguyen (CEPI).
From left to right: Daniela Morich (GHC), Janet Ginnard (Unitaid), Jutta Reinhard-Rupp (FIND), and Aurélia Nguyen (CEPI).

For the Global South, the solution to this systemic paralysis lies not in ad-hoc charity or voluntary donations, but in strict, enforceable obligations under Article 12 of the WHO Pandemic Agreement. This article establishes the pathogen access and benefit-sharing (PABS) system, the details of which are still being negotiated by the IGWG.

Low- and middle-income nations argue that if they share biological materials with the international community, pharmaceutical companies must be legally compelled to share the resulting vaccines, therapeutics, and diagnostics.

Reinforcing this demand, Tangcharoensathien warned the forum that current voluntary and interim mechanisms are vastly inadequate for pandemic preparedness and major crises. He urged the rapid adoption of the PABS annex to regulate how outbreak-prone pathogens and their genetic sequences are shared globally.

To operationalise this, the African Group and the Group for Equity – representing over 80 countries and roughly 75% of the global population – are pushing for standardised contracts that commercial users must sign before accessing any pathogen materials or sequence information.

Proposed mandates for pathogen sharing, a 1.5% revenue tax, and a 20% production reserve.
Proposed mandates for pathogen sharing, a 1.5% revenue tax, and a 20% production reserve.
Budi Gunadi Sadikin demands treating pandemic tools as public goods.
Indonesia’s Minister of Health Budi Gunadi Sadikin wants pandemic tools to be seen as public goods.

Under these proposed agreements, which include Standard Material Transfer Agreements (SMTAs) and Data Access Agreements, commercial users generating revenue from PABS materials would be required to contribute up to 1.5% of their gross revenue to a dedicated fund.

Participating manufacturers would also be legally bound to reserve at least 20% of their real-time production for the WHO during a pandemic, providing a minimum of 10% as donations and the remainder at affordable or not-for-profit prices.

Reflecting the urgency of treating these tools as universal rights rather than market commodities, Indonesian Minister of Health Budi Gunadi Sadikin – a likely contender for the post of WHO director-general in the upcoming elections – made a stark plea to the forum. “During crises, we need to make this a public good…  You cannot play God through this,” he stated in his keynote speech.

Global health funding agencies on the panel strongly supported the demand for legal accountability.

“At the end of the day, until you have something in a contract, you don’t have access,” said Aurélia Nguyen, deputy CEO of the Coalition for Epidemic Preparedness Innovations (CEPI).

Pointing to the urgent need for legally binding agreements, Nguyen noted that funders must act immediately: “We need to be doing that one by one and making sure those access provisions are built in.”

Europe’s ‘global good’ paradox

The contentious debate on pandemic preparedness is playing out against a broader backdrop of rising geopolitical friction and transactionalism in global health policy, Dr Florika Fink-Hooijer, director-general of the European Commission’s Health Emergency Preparedness and Response Authority (DG HERA), pointed out in her keynote remarks.

Florika Fink-Hooijer warns of rising transactionalism in health policy.
Florika Fink-Hooijer (EU) warns of rising transactionalism in health policy.

“We are in a very difficult context,” she warned the forum. “Health has really become transactional.

“Health is something which is a geopolitical instrument. It’s certainly not necessarily treated as a global good, and that we have to bring back,” she urged.

Despite Fink-Hooijer’s appeal for a return to treating health as a global good, the European Union’s approach in practice relies heavily on voluntary partnerships and leveraging a strong private sector.

Fink-Hooijer noted that Europe is investing in mechanisms like joint procurement networks and private-public partnerships to ensure the continent remains “reliable” as a global partner during emergencies.

Recently published official EU policy emphasises that a competitive European health industry is a core pillar of global health resilience.

Contrasting the legally binding Public Good Model against market-driven approaches.
Contrasting the legally binding Public Good Model against market-driven approaches.

Reliance on private investments

Diverging significantly from the strict, legally binding mandates for corporations demanded by the Global South, high-income blocs – including EU member states, Switzerland, and Norway – are pushing to retain anonymous access to pathogen genetic sequence databases.

To accommodate this, an informal “hybrid model” has recently been floated for the PABS system, which includes an “open route” that would allow commercial users to access data without signing binding contracts.

Matthias Seiche emphasises reliance on taxpayer contributions.
Matthias Seiche (Germany) emphasises reliance on taxpayer contributions.

This proposal has been sharply criticised by policy experts at the South Centre and a coalition of over 100 non-governmental organisations, including Oxfam and Medicus Mundi International.

However, Europe’s reliance on the private sector extends to pandemic funding, and European representatives warned that idealistic labels do not magically solve the financial realities of crisis response.

Arguing for models that leverage institutional capital, Germany’s senior diplomat Matthias Seiche cautioned the Geneva panel that whether pandemic funding is framed as Official Development Assistance (ODA) or a global public good, it inherently relies on domestic contributions.

“In the end, it is always the taxpayers’ money that has to be combined from countries all over the world,” he said.

Germany champions limited ‘surge financing’

To circumvent the delays of traditional voluntary funding – and provide a market-driven alternative to the mandatory corporate contributions demanded by the Global South – industrialised nations are instead championing the Global Surge Financing Initiative.

First established in 2024 through a memorandum of understanding signed by development finance institutions from G7 nations, the European Investment Bank (EIB), MedAccess, and the World Bank’s International Finance Corporation (IFC), this mechanism aims at pooling institutional capital to rapidly finance advance purchase agreements for lower-income countries.

The surge financing model combines market-based capital, private-sector reliance, and a hybrid PABS system.
The surge financing model combines market-based capital, private-sector reliance, and a hybrid PABS system.
Viroj Tangcharoensathien remains sceptical of surge financing.
Viroj Tangcharoensathien (IGWG) remains sceptical of surge financing.

Providing “fast and flexible capital” – as the initiative’s partners describe it – through this balance sheet approach would bypass the need to appeal to government finance ministers for grants during the crucial early surge of an outbreak.

Seiche noted that Germany is “in very close and concrete discussions together with the World Bank on putting into place a mechanism to mobilise surge financing at a very large and substantial scale.”

However, fellow panellist Tangcharoensathien expressed scepticism about the initiative. Doubting whether the scale-up mechanism could mobilise adequate support, he argued instead for a sustainable and systematic funding mechanism anchored in the Pandemic Agreement.

Furthermore, he cautioned that because regular monetary contributions under the proposed treaty might ultimately be too small to cover massive emergencies, domestic funding remains the key response.

Acknowledging this limitation, Seiche conceded that while the World Bank mechanism has great potential for the initial weeks of a crisis, longer-term responses will still rely heavily on traditional grant funding.

The ‘scrappy’ interim reality

The recent Ebola outbreak serves as a grim reminder that nature does not wait for treaty negotiations on pandemic preparedness.
The recent Ebola outbreak serves as a grim reminder that nature does not wait for treaty negotiations.

Despite the stark contrast in approaches having led to a deadlock in negotiations on pandemic preparedness, global health expert Moon is “actually optimistic” and “confident” that negotiators will successfully reach a consensus.

Echoing this sentiment, Van Kerkhove agreed that she is “very hopeful” and “confident it will be finished.” Yet, underscoring that the world cannot wait for these highly complex and contested formal negotiations to conclude, she noted that the WHO and its partners are heavily relying on “scrappy” interim frameworks like the Medical Countermeasures Network.

“We don’t want to get ahead of member states, but we need something that’s in place,” she stated. Noting the urgency of the Ebola response, she added: “But … we can’t wait until it’s done. So that’s why we have these interim mechanisms.”

However, with the WHO’s emergency contingency funds critically depleted, the ultimate test remains one of global priorities. As long as the international community remains willing to fund defence spending effortlessly while leaving pandemic preparedness and health crisis mechanisms drained, the world will remain dangerously exposed to the next pandemic threat.

Member States Support Extending Talks on Pandemic Agreement Annex, Propose New ‘Method’

Image Credits: WHO/Joël Lumbala , Felix Sassmannshausen/HPW.

The 79th World Health Assembly adopted the first-ever resolution on steatotic liver disease (SLD) last week. For those people working outside hepatology, the moment may have seemed unremarkable. In reality, it marks an important shift in how the global health community understands chronic disease, metabolic health and prevention.

SLD affects an estimated 1.7 billion people globally and is closely linked to obesity, type 2 diabetes, cardiovascular disease and alcohol-related harm. 

But liver disease matters not only because of its scale. Fat accumulation in the liver is one of the earliest measurable signs of metabolic dysfunction. Long before many people develop cirrhosis, cardiovascular complications or advanced diabetes, the liver is often already signalling that something is wrong.

Importantly, these warning signs can be detected through tools available in routine care: standard blood tests, non-invasive fibrosis scores such as FIB-4, and imaging technologies that can identify fibrosis before symptoms emerge.

In that sense, SLD functions as an early-warning system for the metabolic crisis reshaping societies worldwide – and provides health systems with a critical opportunity to intervene earlier, while disease trajectories can still be changed.

From siloed specialties to integrated care

Yet despite this opportunity, liver health has remained largely absent from noncommunicable disease (NCD) strategies, primary care systems and prevention frameworks.

That omission has consequences. Across countries, liver disease is often identified only after advanced fibrosis, cirrhosis or liver cancer develops. Opportunities for prevention and timely action are frequently missed.

A person attending routine diabetes care may already show elevated fibrosis risk or mildly abnormal liver tests years before serious liver disease develops. Yet these findings often remain disconnected across primary care, endocrinology, cardiology and hepatology.

The problem is not that we lack the tools; what we lack is integration. Much of this earlier risk assessment and intervention could occur in primary care, where obesity, diabetes and cardiovascular risk are already being managed, instead of waiting until people present to specialist clinics with advanced disease.

Recent work from the Global Think-tank on Steatotic Liver Disease and collaborators across Europe has highlighted both the scale of the challenge and the opportunities for action. 

A new Lancet Regional Health – Europe Series shows that Europe’s policy readiness to address metabolic dysfunction-associated steatotic liver disease (MASLD) remains low, even though the condition affects roughly one in three adults and is deeply intertwined with obesity and diabetes.

At the same time, the series demonstrates that many of the tools needed for earlier identification already exist: non-invasive fibrosis testing, automated diagnostic pathways, integrated models of care and digital health systems that make risk stratification increasingly feasible outside hepatology clinics.

Challenge of implementation

The policy challenge now is implementation. That means integrating liver health into national NCD plans, embedding fibrosis risk assessment into obesity and diabetes care, strengthening multidisciplinary care pathways, and measuring late diagnosis so health systems can identify missed opportunities for timely care. 

Done effectively, this could reduce avoidable hospitalisations, liver cancer and downstream cardiovascular complications while improving long-term population health.

These themes were central to discussions held this week in Barcelona at the flagship annual meeting of the Global Think-tank on Steatotic Liver Disease, where clinicians, researchers, policymakers, civil society representatives and people with lived experience met to discuss the future of integrated metabolic health policy.

What emerged clearly was that liver disease is not a niche hepatology issue. It is a visible manifestation of a much wider failure to address metabolic risk early and coherently across health systems.

Prevention, preparedness and political choices

This broader perspective matters especially at a moment when global attention is once again focused on epidemic preparedness following the WHO declaration last week of a public health emergency of international concern (PHEIC) related to Ebola.

The nature of preparedness differs, of course, for acute infectious disease outbreaks and slower-moving chronic diseases. But they often share an uncomfortable reality: societies frequently fail to align policy and resource allocation with the evidence available to them.

That is particularly true for steatotic liver disease.

Too often, global health debates are framed as a choice between responding to acute infectious threats or investing in chronic disease prevention. That is a false dichotomy.

Healthy populations create wealth. Prevention reduces long-term healthcare costs, strengthens productivity and supports more resilient societies. Health economics models repeatedly demonstrate the significant returns associated with timely intervention, innovation and reduced disease burden.

The WHA resolution matters not simply because it acknowledges the gravity of SLD, but because it creates a foundation for integrating liver health into the global NCD response alongside obesity, diabetes and cardiovascular disease.

The liver is already sending early biological signals about the global metabolic health crisis. The question for us now is whether governments and health systems are willing to act while those signals still point to diseases that can be reversed, delayed, or prevented entirely.

Jeffrey Lazarus is Professor of Global Health at CUNY SPH, head of the ISGlobal Public Health Liver Group and Director of the Steatotic Liver Think Tank

Image Credits: Liv Hospital, The Lancet Europe.

China is the powerful new member of the WHO Executive Board.

The World Health Organization’s (WHO) Executive Board (EB) decided on Monday that the first forum for candidates aspiring to become the next Director General will be held on 18 November, where they will face questions from member states.

Meanwhile, some of Africa’s poorest countries will play a decisive role in choosing the next DG, thanks to their membership of the global body’s 34-member EB. The EB has the powerful task of shortlisting three candidates for election by the World Health Assembly (WHA) in 2027.

The Africa region’s seven representatives for the DG selection are Cabo Verde, the Central African Republic (CAR), Côte D’Ivoire, Guinea, Mozambique, South Sudan and Zimbabwe. CAR, South Sudan and Mozambique are among the 10 poorest countries in the world.

On the other end of the spectrum, China is the most powerful new addition to the EB, representing the Western Pacific Region (WPRO). 

WPRO decided at a closed meeting in October 2025 to nominate China to replace Australia, whose term expires this month, as previously reported by Health Policy Watch.

The closed-door nature of the WPRO proceedings suggests this was contentious, which is reinforced by the chair’s report noting that the equitable distribution of seats within WPRO will be revisited for a final decision sometime in 2026. 

Meanwhile, the contentious nature of selecting EB members in the WHO European Region spilt into the open during last week’s WHA, when Russia accused the United Kingdom of depriving it of a seat at the EB.

Georgia and the UK are Europe’s new EB representatives, replacing Switzerland and Ukraine whose terms end this month. The European Region decided a while back that its permanent members of the UN Security Council are entitled to EB membership for three out of every six years.

This accounts for the UK’s selection, with France already confirmed as its replacement. However, Russia, which is also on the Security Council, was not afforded the same rotating privileges and stood as a competing candidate for the seat ultimately won by Georgia.

Election process outlined

On 24 April, Dr Tedros issued an invitation to member states to make nominations for Director General by 24 September, officially kicking off a period of intense lobbying for the most powerful position in global health.

The official announcement of candidates for the post of Director-General will take place after the closure of the last regional committee session before the session of the Executive Board at which the nomination will take place (that is, on or after 29 October 2026

The EB, which met in Geneva on Monday, adopted a report by the Director General outlining the election process.

According to this process, two candidates’ forums will be convened by the WHO Secretariat to enable the candidates to make themselves and their vision known to member states. 

The first forum, starting on 18 November and continuing for not more than three consecutive days, depending on the number of initial candidates. Each candidate will get 60 minutes, made up of a 10-minute presentation followed by a question-and-answer session.

The second forum on 15 March 2027 will consist of a more interactive panel discussion between the candidates and member states.

Institutional stability

Guinea supported placing internal WHO candidates on leave during the election process.

Addressing the EB on Monday, China said that the DG election procedures “established through Board consultations among member states over the past few years have played a positive role in maintaining institutional stability and continuity of work”.

China emphasised “the need to continue respecting the intergovernmental nature of the WHO, safeguarding the equal participation rights of all member states, especially developing countries, and providing sufficient opportunities for member states to learn about candidates in an objective, orderly, and transparent manner”.

Guinea supported the report, clarifying that potential candidates could attend regional meetings but not campaign during these, describing this as “excellent for the calm development [of the process]”.

Guinea also welcomed clarity on the status of internal candidates, who will be placed on special leave at half pay initially – then full pay if the EB nominates them as one of the three candidates for the WHA. 

“This differentiation between work within the WHO and campaigning is essential to preserve the integrity of the organisation,” said Guinea, which also supported the drawing of lots by region to determine the order of appearance of the candidates at the two public forums.

Germany, which is likely to nominate a DG candidate, outlined some of the qualities needed by the position.

Germany, which is contemplating a couple of potential nominations, stressed that the “next DG will inherit an organisation that has gone through significant challenges. To be successful, we need to see [a candidate with] a commitment to champion necessary reform and a distinct focus for delivering on the organisation’s core mandate in the future”.

Germany wants its financial weight reflected as the largest global health donor following the US withdrawal from the WHO in January 2025.

The most likely German candidate is Helge Braun, Chief of Staff in former Chancellor Angela Merkel’s government, insiders told Health Policy Watch.

Norway noted that the new DG “will take office in a highly challenging and polarised time, multilaterally, financially, and globally. 

“He or she must have both political acumen, as well as excellent unifying and administrative skills. Previous leadership experience from a large organisation would be desirable, in addition to solid health experience and policy experience. The new DG must strive to ensure a reformed and strengthened WHO in a more unified, coordinated, and resource-efficient UN system,” said Norway.

lung heathclimate change
Children with asthma are especially vulnerable to the climate-related exposures like air pollution and heat waves.

The impact of climate on respiratory health was the subject of a meeting alongside the World Health Assembly (WHA) in Geneva. This comes as the UN General Assembly endorsed a landmark International Court of Justice ruling that holds countries accountable to curb greenhouse gas emissions.

“Imagine you are running. You are tired and want to stop. But I keep telling you to run. You can’t breathe,” said Dr Helena Pité, describing what it means to have a ‘lung attack,’ which can be caused by asthma, chronic obstructive pulmonary disease (COPD), or an allergic reaction. 

The Lisbon allergist and respiratory expert from Hospital CUF Tejo outlined how climate change is linked to lung inflammation through longer pollen seasons, severe wildfires, air pollution, and extreme heat. 

Respiratory health was central to a discussion on climate change at the Geneva Health Forum, and came as the Pan-European Commission on Climate and Health (PECCH) released new recommendations in The Lancet for the fastest-warming continent. 

The report calls on the World Health Organization (WHO) and heads of governments to confront climate change as a “catastrophic threat to human health, security, and social stability.”

Furthermore, the authors urge the WHO to formally declare climate change a public health emergency of international concern (PHEIC) on par with the recent Ebola outbreak, COVID-19, and mpox.   

Climate change destabilizes the four pillars needed for health: access to food, water, shelter, and clean air, said Dr Maria Neira, former WHO director for the department of Public Health, Environment and Social Determinants of Health. 

“This is not just a matter of reducing emissions,” she said, but “a negotiation for our health.”

Air quality and climate change 

Delhi air pollution during peak days in mid-November 2025.

The connection between climate change and health began more than 30 years ago, when the scientific evidence base quickly outpaced any sort of action. 

A landmark 2008 WHA resolution on climate and health pushed member states to take urgent action to develop what it termed “health measures” and to “integrate them into plans for adaptation to climate change as appropriate,” among four other action items.

“Health is the argument for climate action,” Neira argued. The  causes of climate change and the causes of air pollution overlap 85%–the UN Environment Programme calls the combustion of fossil fuels “two sides of the same coin.” 

This is why Neira and others at the intersection of climate and health see climate treaties as “the best public health treaties” with innumerable benefits.

Allergies and asthma 

Seven-year old Princess developed asthma growing up near coal mines in Emaalahleni, South Africa.

Roughly one in three people will suffer from allergies during their lifetime, whether from seasonal, food, medicinal, or animal bite allergens. 

Pite is seeing more and more patients with severe environmental allergies and asthma conditions. Her patients are now younger than she’s seen in her 20 years of practice.

Her Lisbon-based practice sees patients with severe allergies and asthma – and the Portuguese city’s extended pollen season is only exacerbating the problem. 

“Plants are suffering,” she said in explaining the longer seasons. Rising temperatures due to climate change have exacerbated pollen seasons, driving plants to produce more of the irritating substance earlier and for prolonged periods.  

In the US, Australia, and across Europe, pollen levels have risen in the past decades, causing discomfort in many and severe respiratory distress in others. 

This is why Pite hopes to reframe the narrative around climate change and respiratory health: “People know that air pollution can cause heart attacks–that extreme heat can do that. But what about a ‘lung attack?’” She argued that more education for medical professionals on climate risks–and proactive policies to prevent lung attacks–would mean less suffering for the vulnerable: children, those with chronic diseases, and older adults.

It’s just one health outcome that can be linked to climate change, but oftentimes the most severe, as Neira argued in saying the price of climate change is “paid by our lungs.” 

Life dictated by avoiding heatwaves and pollutants

Climate changeHeat wave
Berliners cooling off during a summer heat wave.

For patients living with these conditions, day-to-day life is often dictated by avoiding climate change hazards, Panagiotis Chaslaridis, a senior policy advisor at the European Federation for Patients with Allergies and airway diseases (EFA). His organization represents patients with chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and other conditions. 

“Patients have to be especially vigilant,” his organization’s website warns. One such patient, identified only by her first name, Kelly, shared her story with the UK’s Asthma + Lung advocacy group. She said she was “forced to move out” of central London after 14 life-threatening asthma attacks, which she attributes to the city’s air. Now, she’s worried for her one-year-old daughter, who has been rushed to the hospital twice for breathing difficulties. “We’ve decided to move farther out of London to the seaside,” she told the advocacy organization.

Europe is the fastest warming continent with an average increase of 0.56 C per decade since the mid-1990s. That’s nearly twice the global rate of 0.27 C per decade.

The PECCH Lancet report calls on ministries of health to embed climate-health topics into health profession education–and integrate climate change considerations into disease management. 

“Climate change poses significant health risks for patients with chronic respiratory diseases, allergies, and skin conditions. These environmental hazards are no longer distant threats; they are becoming increasingly prevalent in Europe,” the EFA continues. 

Neira and Pite also called for national health systems to track health outcomes linked to climate crises–so that countries can track just how much a burden heatwaves, air pollution, and prolonged pollen seasons have on their health systems. 

The role of cities

Health experts see cities as the pioneers for action. The built environment–buildings, schools, and homes–is one frontier the UN Environmental Programme has charted metrics of climate progress.

Cities like London, Barcelona, and Nairobi are all pioneering solutions, such as ultra-low-emission zones, green spaces, congestion pricing, bike lanes, and urban gardens. The group C40 Cities has brought together a coalition of over 90 mayors to implement and share lessons learned from these solutions. 

“Across the world, mayors are showing that good urban planning is climate action, from creating more connected and inclusive communities, to reducing emissions and protecting people from growing climate risks,” the group’s CEO Mark Watts said in a  statement. “The decisions cities make today about how they grow and develop will shape the resilience, health, and prosperity of urban residents for generations to come.”

Neira sees mayors as the real leaders for climate-health action–especially for their ability to bridge multiple sectors. She explained that improving the lives of millions of people with respiratory diseases depends on coordination between the ministries of health, transport, environment, and energy. The Lancet PECCH report also echoes this call for coordination.

At the launch of the PECCH, WHO European regional director Hans Kluge said: “We have known for years what climate change does to human health. What we have lacked is the political architecture to act at the scale the evidence demands.”

Kluge asked the commission to “close that gap – not by producing more analysis, but by translating what we know into actionable recommendations that governments and WHO itself can no longer defer into the future.”

UN approves International Court of Justice climate ruling

This all comes at a particularly critical time in global climate action. As member states gathered in Geneva for the World Health Assembly, the UN General Assembly endorsed a landmark decision by the International Court of Justice which ruled international law binds countries to limit the carbon emissions driving the climate crisis

The Hague-based ICJ ruling holds significant “symbolic weight,” especially for bolstering legal arguments in climate litigation. Likely, though, major greenhouse gas emitters will ignore the ICJ ruling.

What this means for health is yet to be seen–especially for those suffering from “lung attacks” across the world.

See related story: https://healthpolicy-watch.news/un-backs-landmark-icj-climate-crisis-ruling-defying-us-and-petrostates/

Image Credits: Kelly Sikkema/ Unsplash, Chetan Bhattacharji, Dylan Paul, Center for Environmental Rights, CC.

GENEVA — Hundreds of hours of formal negotiations and corridor-side bargaining in the halls of the United Nations (UN) Palais des Nations and World Health Organization (WHO) headquarters this week ended on Saturday afternoon – more or less on schedule, an outcome rare enough at the UN to be cause for celebration.

The sunshine, Mont Blanc’s snow-covered peak, the shining waters of Lake Geneva, and the fancy canapés circulating at side-event receptions were a sharp contrast to the storm of crises unfolding in the global health world throughout the week.

A fresh Ebola emergency ripping through the Democratic Republic of Congo. The tail end of a hantavirus outbreak. Diplomatic wars over conflicts in Iran, Lebanon, Gaza and Ukraine. And a WHO finding, released days before the assembly, that the world is on track to miss every single health-related UN 2030 development goal.

Between the headlines on the global health financing emergency, WHO’s declining budget, Argentina’s withdrawal from the organisation and the first-ever absence of the United States — whose voting rights were formally suspended for the 2027 Assembly for its failure to pay membership dues — member states quietly adopted more than 20 decisions and 13 new resolutions.

Several updated health frameworks decades to over half a century old. Most went unnoticed. Here’s what they decided.

Stop stealing our health workers!

Perhaps the most consequential unnoticed text adopted this week was the first revision in 16 years of the WHO Global Code of Practice on the International Recruitment of Health Personnel – the people on whom, after all, every other resolution depends.

Ahead of the assembly, an Expert Advisory Group appointed by the WHO to conduct the third review in the Code’s 16-year history delivered a verdict on its efficacy. Unusually direct for a UN document, they noted that it is not working.

“High-income destination countries make substantial savings on the costs of health professional education through international recruitment, while the desired investments in the health systems of developing source countries have not materialised to yield the expected proportional benefits,” the expert group said.

The updated recommendations now explicitly cover health personnel recruited abroad to work as care workers, closing a loophole that wealthy, ageing societies have used to staff elder care with workers trained in lower-income countries.

The new recommendations also apply during “pandemics and other health emergencies, environmental disasters and humanitarian, economic or crises situations”, a change intended to stop wealthy destination countries from treating ethical recruitment as a fair-weather principle.

During COVID-19, several high-income countries accelerated the recruitment of nurses and doctors from the Philippines, India and across sub-Saharan Africa, even as those countries’ systems strained under the pandemic.

“The continuous migration of skilled health workers from source countries like ours directly weakens our primary health system and our path to universal health coverage,” Eswatini’s delegate told the committee.

“We call on destination countries to uphold ethical recruitment standards on bilateral commitments and support health workforce strengthening in source countries.”

A WHO assessment of 108 low- and lower-middle-income countries earlier this year found that 63% had already reported job losses, salary suspensions or cuts among health and care workers as a result of donor aid retrenchment. Nearly 70% anticipated future recruitment problems.

Speaking at the WHA, Jamaica, which “continues to experience the impact of migration of skilled health professionals, particularly nurses, midwives, and allied health workers,” emphasised that “recruitment practices must not compromise the source country’s health systems.”

Its delegation added Jamaica is now negotiating south-south agreements with the Philippines, India, Ghana and Nigeria – hinting that source countries are tiring of waiting for destination countries to follow the WHO’s rules.

Wealthy destination countries, despite drawing millions of healthcare professionals to their systems, are in crisis too.

The WHO European region, which absorbs much of the workforce migration, faces a shortfall of 1.8 million health workers, expected to double to four million by 2030. WHO Europe Director Hans Kluge has called the region’s workforce crisis a “ticking time bomb.”

A stroke of progress

For the world’s second-leading cause of death and third-leading cause of disability, stroke has spent decades waiting for its turn at the WHA. On Friday, that finally changed.

The first-ever WHA resolution dedicated to stroke, led by Egypt and co-sponsored by Chile, Georgia, Palestine, Paraguay and Tunisia, addresses a disease responsible for an estimated 11.9 million new cases globally in 2021.

In high-income countries, the typical stroke patient is older and presents at a hospital equipped with CT scanners, preventive drugs and stroke units.

In LMICs, the patient is often younger and hypertensive, and often reaches care, if at all, too late for the time-sensitive interventions that determine whether stroke is survivable or fatal.

The gap in care standards creates a seismic inequality. As new stroke cases rose 70% from 1990 to 2021, 87% of stroke deaths occur in low- and middle-income countries. New stroke deaths rose 44% over the same period.

The resolution noted that only one in three adults in LMICs is aware they have hypertension and only around 8% have it under control.

The result is a higher prevalence of haemorrhaging strokes — the most lethal variety, which results from years of uncontrolled blood pressure — in poorer countries, leading to more deaths. Tobacco, air pollution, salt-heavy diets and limited access to preventive primary care push the mortality risks even higher.

Egypt, leading the resolution as part of a four-text package that also covered teleradiology, pharmacovigilance and precision medicine, stressed “the urgency of integrated national responses to strengthen prevention, early detection, acute care, rehabilitation, and long-term support, particularly in low and middle-income countries, where the [stroke] burden continues to rise.”

Cold War-era guidelines updated

If stroke waited decades for a resolution, the global system for monitoring whether medicines are killing the people taking them has waited longer.

The Berlin Wall went up and came down, the Soviet Union dissolved, Russia invaded Ukraine twice – and the WHO’s pharmacovigilance architecture stayed where it was.

The architecture prior to WHA dated to resolution WHA16.36, adopted in 1963 in the aftermath of the thalidomide tragedy. The sedative, marketed to pregnant women across 46 countries to treat morning sickness in the early Cold War era, caused an estimated 10,000 to 12,000 babies to be born with severe limb malformations.

The 1963 resolution called for member states to systematically collect reports of serious adverse drug reactions. Pharmacovigilance — the WHO’s term for that surveillance — has not been substantively updated at this level since.

This week’s resolution teleports that framework into the era of COVID-19, real-world data and artificial intelligence. It calls on countries to leverage AI and machine learning “in a safe, transparent and ethical manner to improve safety signal detection and response, while also maintaining public trust.”

The recognition matters because pandemic-era mRNA vaccines and antivirals were rolled out in months, and post-marketing safety signals had to be tracked across populations of billions. The infrastructure built around paper reports and national centres was not designed for the speed or scale of modern global health crises.

“Significant inequities persist in pharmacovigilance capacity, with many developing countries facing capacity and resource constraints and contributing a disproportionately small share of global safety data, resulting in populations being unequally protected against adverse events,” the resolution states.

In other words, drug safety standards around the world are uneven because the quality and scale of surveillance data is uneven.

A similar gap is reflected in the gender divide, where women face a higher rate of adverse reactions due to data over decades of pharmacovigilance trials primarily focusing on men, the resolution says.

Tanzania’s delegation called the updated text “an essential pillar of patient safety, resilient health systems, and public trust.”

WHO will report back on implementation in 2028, 2030 and 2032.

Emergency care gets a nod

An estimated 38 million people die every year from conditions that emergency rooms, operating theatres and intensive care units could treat if patients could reach them in time, according to the new global strategy adopted this week, which notes the same conditions cause 1.3 billion disability-adjusted life years lost annually.

The new Integrated Emergency, Critical and Operative Care Strategy 2026–2035 gives countries a 10-year framework to fix one of the most glaring inequalities in global health: where this care is available, lives are saved; where it is not, the gap is stark.

“Globally, 6% of surgical procedures occur in low-resource countries, despite those being home to over a third of the world’s population,” the International Federation of Medical Students’ Associations told the committee.

Tens of millions of people, most of them in lower-middle-income countries, face catastrophic health expenditure from emergency care every year, the resolution states.

Tens of millions more face catastrophic expenditure from the non-medical costs alone — transport, food, lodging — of trying to reach a hospital with an emergency ward equipped to deal with critical health conditions, from childbirth complications and road traffic injuries to heart attacks, strokes, sepsis, malaria, diarrhoeal disease and pneumonia.

“Ukraine’s experience during Russia’s ongoing aggression shows that critical care must function as a continuum from prehospital response to surgery and rehabilitation,” Ukraine’s delegate told the committee. “We support strengthening workforce capacity, referral systems, and digital tools, especially in conflict-affected settings.”

Burkina Faso, hit by years of militant insurgent violence in the Sahel, described the pressure on its health system “in particular in terms of trauma care, critical care, and emergencies”. Its regional neighbour Chad also pressed the importance of the strategy “for countries facing humanitarian security in health crises, particularly in the Lake Chad Basin affected by terrorist attacks by Boko Haram.”

On the sidelines of the assembly, Ethiopia, Germany and Brazil launched the Global Health Emergency Corps Strategy, aiming to ensure 10% of every country’s health workforce is “organised, trained, exercised and connected to respond to emergencies by 2030.”

WHO will publish an action plan with targets by the end of 2026.

Remote radiology to the rescue

Another resolution on teleradiology, also led by Egypt, aims to make it easier for specialists in one country to read scans from another.

Teleradiology — the secure digital transmission of medical images for remote interpretation — has existed for decades, but its uneven uptake has left many countries with imaging machines and no one trained to read what they produce.

“The absence of trained personnel to interpret the images, or weak referral systems, leads to suboptimal utilisation of the equipment and may limit the effective use of existing imaging capacity,” the resolution notes.

The technology allows expertise to travel where infrastructure cannot. A radiologist in Cairo can read a scan taken in northern Mali. The same arrangement lets a doctor in a safer country read a chest X-ray from a besieged hospital in Khartoum, or a stroke scan from a frontline in eastern Ukraine.

The resolution builds in artificial intelligence as a clinical aid, requiring AI tools to be “developed, validated, safely deployed and governed ethically.”

“These solutions help bridge geographical barriers, strengthen diagnostics across islands, and reduce dependence on overseas referrals,” the Maldives told the committee.

Fiji noted that “digital X-ray systems with embedded artificial intelligence are now being deployed nationwide to improve diagnostic speed, accuracy, and equitable access to healthcare.”

The resolution requests a situation report back to WHA in 2030.

Two decades, missing genomes

The first WHA resolution on precision medicine updates a 22-year-old text on genomics and world health, adopted in 2004 when the human genome had only just been sequenced, and the cost of doing so ran into the millions of dollars per patient.

Today, sequencing giant Illumina says its reagents can sequence a human genome for under $200.

Precision medicine — the use of genomic, molecular and clinical data to tailor prevention, diagnosis and treatment — has delivered measurable gains in cancer survival, faster diagnosis of rare diseases, and safer prescribing, WHO said.

But this miracle of modern medicine is not available to everyone.

“Many populations, particularly women, children and older adults, remain underrepresented in the data and research that underpin precision medicine,” the resolution states, pointing to “developing countries facing limited laboratory infrastructure, underrepresentation in genomic and clinical datasets, shortage of skilled professionals, and inadequate governance mechanisms for ethical data use and sharing.”

A medicine designed using genomes drawn predominantly from people of European ancestry will work less well — sometimes much less well — on populations whose ancestry is not represented.

Without governance, the technology that promised to deliver the right treatment to the right patient at the right time risks delivering it only to the right zip code.

Egypt’s delegation emphasised precision medicine and AI-driven diagnostics “must remain accessible and affordable to all, so that it becomes a tool for equity rather than a source of widening disparities.”

The resolution aligns with last year’s WHA decision on rare diseases, which Egypt also championed. Nearly 80% of rare diseases are genetic, making precision medicine and rare disease policy two halves of the same agenda.

WHO will deliver a global strategy on precision medicine to the 82nd WHA in 2029.

Radiation in a year of nuclear strikes

The assembly’s first-ever comprehensive resolution on radiation and health, sponsored by Armenia, Chile, Egypt, Iraq, Palestine, Qatar, Saudi Arabia, Thailand and Tunisia, was adopted in a year marked by missiles, drones and projectiles striking or landing near nuclear facilities across three continents.

The resolution covers both ionising radiation (from medical imaging, radiotherapy, radon and nuclear sources) and non-ionising radiation (ultraviolet, electromagnetic fields) — a unified framework that previous WHA resolutions had treated seperately.

It acknowledges health risks to children and pregnant women, the increasing use of radiopharmaceuticals in cancer care, and “the non-radiological health impacts of radiation emergencies.”

The resolution explicitly recalls last year’s resolution on the health effects of nuclear war, a text the World Health Assembly fought bitterly over before adopting.

Russia and North Korea opposed it, saying there was nothing left for WHO to study. The Marshall Islands, Micronesia, other Pacific island states, Iraq and Kazakhstan pushed it through, citing decades of documented cancers, birth defects and chronic illness still afflicting populations near former Cold War test sites in the Pacific atolls and the Kazakh steppes generations after the last detonations.

The day before the assembly formally opened, a drone strike sparked a fire on the perimeter of the United Arab Emirates’ Barakah Nuclear Energy Plant, the first nuclear power station on the Arabian Peninsula. The strike drew “grave concern” from International Atomic Energy Agency Director-General Rafael Grossi, and featured as a pivotal part of the debate over a separate WHA resolution adopted this week on the public health consequences of Iranian attacks on civilian infrastructure across Gulf states and Jordan.

Earlier this year, projectiles struck near Iran’s Bushehr nuclear plant twice in eight days, and missiles were fired in the direction of Israel’s Dimona nuclear research centre. Russian forces continue to occupy the Zaporizhzhia nuclear plant in Ukraine, which remains disconnected from the country’s electrical grid and dependent on emergency diesel generators to cool its reactors — a worst-case-scenario configuration the IAEA has repeatedly warned poses ongoing radiological risk.

The resolution requests a global mapping of “relevant actors and initiatives” in radiation and health by 2028.

We have the text, but where’s the money?

The assembly closed by adopting a strategy on the economics of health for all for 2026–2030, building on the work of WHO’s Council on the Economics of Health for All.

The text is ideologically the most ambitious of the week: a “well-being economy” framework calling for governments to use tax, trade, industrial and labour policy as health levers, address “harmful commercial practices,” and confront the “financialization of healthcare delivery.”

It is also the text most exposed to the gap WHO itself now openly calls a “global health financing emergency.”

Global development assistance for health fell 21% between 2024 and 2025, driven almost entirely by a 67% drop in US financing — more than $9 billion — according to data from the Institute for Health Metrics and Evaluation.

But the US is not alone: Germany cut its bilateral health aid by 53%, the UK by 39%, and France by 33%. Total OECD official development assistance fell 23.1% in 2025, the largest single-year contraction on record.

That financing gap is the wall every resolution adopted this week will hit on its way out the door. The World Health Assembly issues guidance; it does not mobilise funds. Unlike UN climate summits, where the headline negotiation each year is over hundreds of billions to trillions of dollars in financing requests from global south countries, the WHA passes rules that national governments must then choose to fund on their own.

As African leaders at the Nairobi World Health Summit last month declared the end of the aid era, a Centre for Global Development audit found that only two African countries proposed new revenue measures to replace lost financing in their 2025 budgets, and none reprioritised spending from other sectors to protect health.

In other words: aid is gone, and the countries it left behind are not — for the most part — yet in a position to replace it.

The crisis framing of the global health funding shortfall stands in stark contrast to the reality that the missing money is, in global terms, comparatively negligible. Year after year, governments choose tanks over hospitals, missiles over medicines, and submarines over the surveillance systems that catch the next pandemic before it spreads.

The $9 billion gap left by US withdrawal is roughly 2.4% of EU defence spending and 0.66% of combined EU-US defence outlays for 2024. EU defence expenditure alone rose to €381 billion in 2025, a 19% increase on the previous year.

Around 200 individuals with net worths above $10 billion hold approximately $5 trillion between them. The combined fortunes of the world’s three richest men — Musk, Google co-founder Larry Page ($257 billion), and Google co-founder Sergey Brin ($237 billion) — could fund the gap for 148 years, until the early 22nd century.

“Every resolution you adopt, every agreement you reach, only has value when it changes what happens in a clinic, in a community, or in a household,” WHO Director-General Tedros Adhanom Ghebreyesus told delegates in his closing remarks on Saturday evening. “When a health worker has what they need to do their job; when a child is vaccinated; when a mother survives childbirth; when an outbreak is contained before it spreads. That is now the task before us.”

The resolutions adopted this week, by any reasonable read, are good policy. Stroke needs a stroke unit. Drug safety needs surveillance. Genomes need to be sequenced from populations they will be used to treat. Health workers cannot be poached without consequence from countries that trained them. Emergencies do not respect borders.

But none of the resolutions are binding. They will sit in the WHO archive unless governments — finance ministries more than health ministries — find the money and the political appetite to implement them.

The history of the World Health Assembly is, among other things, a history of resolutions that did not. Whether any of the new resolutions become more than pages in the archive will not be decided in Geneva.

Image Credits: Chetan Bhattacharija .